Bollmann Marc-Daniel, Revelly Jean-Pierre, Tappy Luc, Berger Mette M, Schaller Marie-Denise, Cayeux Marie-Christine, Martinez Alexandre, Chioléro René-Louis
Surgical Intensive Care Unit, University Hospital CHUV, 1011 Lausanne, Switzerland.
Intensive Care Med. 2004 Jun;30(6):1103-10. doi: 10.1007/s00134-004-2251-3. Epub 2004 Mar 27.
To compare the effects of sodium bicarbonate and lactate for continuous veno-venous hemodiafiltration (CVVHDF) in critically ill patients.
Prospective crossed-over controlled trial in the surgical and medical ICUs of a university hospital.
Eight patients with multiple organ dysfunction syndrome (MODS) requiring CVVHDF.
Each patient received the two buffers in a randomized sequence over two consecutive days.
The following variables were determined: acid-base parameters, lactate production and utilization ((13)C lactate infusion), glucose turnover (6,6(2)H(2)-glucose), gas exchange (indirect calorimetry). No side effect was observed during lactate administration. Baseline arterial acid-base variables were equal with the two buffers. Arterial lactate (2.9 versus 1.5 mmol/l), glycemia (+18%) and glucose turnover (+23%) were higher in the lactate period. Bicarbonate and glucose losses in CVVHDF were substantial, but not lactate elimination. Infusing (13)C lactate increased plasma lactate levels equally with the two buffers. Lactate clearance (7.8+/-0.8 vs 7.5+/-0.8 ml/kg per min in the bicarbonate and lactate periods) and endogenous production rates (14.0+/-2.6 vs 13.6+/-2.6 mmol/kg per min) were similar. (13)C lactate was used as a metabolic substrate, as shown by (13)CO(2) excretion. Glycemia and metabolic rate increased significantly and similarly during the two periods during lactate infusion.
Lactate was rapidly cleared from the blood of critically ill patients without acute liver failure requiring CVVHDF, being transformed into glucose or oxidized. Lactate did not exert undesirable effects, except moderate hyperglycemia, and achieved comparable effects on acid-base balance to bicarbonate.
比较碳酸氢钠和乳酸盐在危重症患者连续性静脉-静脉血液透析滤过(CVVHDF)中的效果。
在一所大学医院的外科和内科重症监护病房进行的前瞻性交叉对照试验。
8例需要CVVHDF的多器官功能障碍综合征(MODS)患者。
每位患者在连续两天内按随机顺序接受两种缓冲液。
测定了以下变量:酸碱参数、乳酸生成与利用((13)C乳酸输注)、葡萄糖周转率(6,6(2)H(2)-葡萄糖)、气体交换(间接测热法)。输注乳酸盐期间未观察到副作用。两种缓冲液的基线动脉酸碱变量相等。乳酸盐期的动脉乳酸水平(2.9对1.5 mmol/l)、血糖(升高18%)和葡萄糖周转率(升高23%)更高。CVVHDF中碳酸氢盐和葡萄糖的丢失量很大,但乳酸盐清除量不大。输注(13)C乳酸盐使两种缓冲液的血浆乳酸水平升高程度相同。乳酸盐清除率(碳酸氢盐期和乳酸盐期分别为7.8±0.8 vs 7.5±0.8 ml/kg每分钟)和内源性生成率(14.0±2.6 vs 13.6±2.6 mmol/kg每分钟)相似。(13)C乳酸盐被用作代谢底物,(13)CO(2)排泄情况表明了这一点。输注乳酸盐期间的两个阶段,血糖和代谢率均显著且相似地升高。
在需要CVVHDF且无急性肝衰竭的危重症患者血液中,乳酸盐能迅速清除,可转化为葡萄糖或被氧化。除了中度高血糖外,乳酸盐未产生不良影响,且在酸碱平衡方面与碳酸氢盐效果相当。